ArticleCancer gene therapy2012
Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Article in Cancer gene therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy.Genes & diseases · 2025Review
- Viral Vector-Based Cancer Vaccines.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Iodine-125 seed inhibits proliferation and promotes apoptosis of cholangiocarcinoma cells by inducing the ROS/p53 axis.Functional & integrative genomics · 2024Article
- OncolyticTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024Article
- Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma.Pathogens (Basel, Switzerland) · 2024Article
- Engineering and combining oncolytic measles virus for cancer therapy.Cytokine & growth factor reviews · 2020Review
- Virotheranostics, a double-barreled viral gun pointed toward cancer; ready to shoot?Cancer cell international · 2020Review
- Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer.Cancers · 2019Review
- Gene Therapy Today and Tomorrow.Diseases (Basel, Switzerland) · 2019Article
- Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.BMC cancer · 2018Article
- Viral Vectors in Gene Therapy.Diseases (Basel, Switzerland) · 2018Review
- Potential and clinical translation of oncolytic measles viruses.Expert opinion on biological therapy · 2017Review
- Oncolytic viruses-immunotherapeutics on the rise.Journal of molecular medicine (Berlin, Germany) · 2016Review
- The current status of oncolytic viral therapy for head and neck cancer.World journal of otorhinolaryngology - head and neck surgery · 2016Review
- The use of the NIS reporter gene for optimizing oncolytic virotherapy.Expert opinion on biological therapy · 2016Review
- Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain.Oncotarget · 2015Article
- PET imaging of oncolytic VSV expressing the mutant HSV-1 thymidine kinase transgene in a preclinical HCC rat model.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Oncolytic virotherapy for head and neck cancer: current research and future developments.Oncolytic virotherapy · 2015Review
- Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma.Oncolytic virotherapy · 2015Article
- Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm.Journal of experimental & clinical cancer research : CR · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic thyroid cancer is an extremely aggressive disease resistant to radioiodine treatment because of loss of sodium iodide symporter (NIS) expression. To enhance prognosis of this fatal cancer, we validated the preclinical efficacy of measles virus (MV)-NIS, the vaccine strain of the oncolytic MV (MV-Edm), modified to include the NIS gene. Western blotting analysis confirmed that a panel of eight anaplastic thyroid cancer (ATC)-derived cell lines do not express NIS protein, but do express CD46, the MV receptor. In vitro cell death assays and in vivo xenograft studies demonstrate the oncolytic efficacy of MV-NIS in BHT-101 and KTC-3, ATC-derived cell lines. Radioactive iodine uptake along with single-photon emission computed tomography (SPECT)-computed tomography imaging of KTC-3 xenografts after (99)Tc(m) administration confirmed NIS expression in vitro and in vivo, respectively, after virus treatment. Adjuvant administration of RAI, to MV-NIS-treated KTC-3 tumors showed a trend for increased tumor cell killing. As current treatment for ATC is only palliative, and MV-NIS is currently Food and Drug Administration approved for human clinical trials in myeloma, our data indicate that targeting ATC with MV-NIS could prove to be a novel therapeutic strategy for effective treatment of iodine-resistant ATC and will expedite its testing in clinical trials for this aggressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.